InterCure (INCR) Competitors

$0.85 -0.01 (-0.94%)

As of 03:02 PM Eastern

INCR vs. IFRX, ADAG, LFCR, PRQR, and PYXS

Should you buy InterCure stock or one of its competitors? MarketBeat compares InterCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InterCure include InflaRx (IFRX), Adagene (ADAG), Lifecore Biomedical (LFCR), ProQR Therapeutics (PRQR), and Pyxis Oncology (PYXS). These companies are all part of the "pharmaceutical products" industry.

How does InterCure compare to InflaRx?

InflaRx (NASDAQ:IFRX) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

InflaRx currently has a consensus price target of $7.00, suggesting a potential upside of 178.88%. Given InflaRx's stronger consensus rating and higher probable upside, research analysts plainly believe InflaRx is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, InflaRx had 1 more articles in the media than InterCure. MarketBeat recorded 1 mentions for InflaRx and 0 mentions for InterCure. InflaRx's average media sentiment score of 0.00 equaled InterCure'saverage media sentiment score.

Company	Overall Sentiment
InflaRx	Neutral
InterCure	Neutral

InterCure has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	6,048.26	-$51.63M	-$0.71	N/A
InterCure	$78.47M	0.60	-$10.37M	$0.03	28.60

InflaRx has a beta of 2.42, suggesting that its stock price is 142% more volatile than the broader market. Comparatively, InterCure has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

InterCure's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
InterCure	N/A	N/A	N/A

Summary

InflaRx beats InterCure on 9 of the 15 factors compared between the two stocks.

How does InterCure compare to Adagene?

Adagene (NASDAQ:ADAG) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Adagene currently has a consensus target price of $8.00, indicating a potential upside of 111.92%. Given Adagene's stronger consensus rating and higher probable upside, equities analysts clearly believe Adagene is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Adagene had 1 more articles in the media than InterCure. MarketBeat recorded 1 mentions for Adagene and 0 mentions for InterCure. Adagene's average media sentiment score of 0.15 beat InterCure's score of 0.00 indicating that Adagene is being referred to more favorably in the media.

Company	Overall Sentiment
Adagene	Neutral
InterCure	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
InterCure	N/A	N/A	N/A

InterCure has higher revenue and earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	23.32	-$17.61M	N/A	N/A
InterCure	$78.47M	0.60	-$10.37M	$0.03	28.60

Adagene has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, InterCure has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

9.5% of Adagene shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Adagene beats InterCure on 9 of the 12 factors compared between the two stocks.

How does InterCure compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Lifecore Biomedical currently has a consensus target price of $6.00, suggesting a potential upside of 23.00%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, equities analysts clearly believe Lifecore Biomedical is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, InterCure has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by insiders. Comparatively, 0.2% of InterCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Lifecore Biomedical had 1 more articles in the media than InterCure. MarketBeat recorded 1 mentions for Lifecore Biomedical and 0 mentions for InterCure. Lifecore Biomedical's average media sentiment score of 0.38 beat InterCure's score of 0.00 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Lifecore Biomedical	Neutral
InterCure	Neutral

InterCure has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. InterCure's return on equity of 0.00% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
InterCure	N/A	N/A	N/A

InterCure has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.42	-$35.26M	-$0.94	N/A
InterCure	$78.47M	0.60	-$10.37M	$0.03	28.60

Summary

Lifecore Biomedical beats InterCure on 9 of the 16 factors compared between the two stocks.

How does InterCure compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

InterCure has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.52	-$47.73M	-$0.50	N/A
InterCure	$78.47M	0.60	-$10.37M	$0.03	28.60

In the previous week, ProQR Therapeutics had 5 more articles in the media than InterCure. MarketBeat recorded 5 mentions for ProQR Therapeutics and 0 mentions for InterCure. ProQR Therapeutics' average media sentiment score of 0.16 beat InterCure's score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
ProQR Therapeutics	Neutral
InterCure	Neutral

ProQR Therapeutics presently has a consensus price target of $7.25, suggesting a potential upside of 398.28%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe ProQR Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InterCure has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. InterCure's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
InterCure	N/A	N/A	N/A

ProQR Therapeutics has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market. Comparatively, InterCure has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 0.2% of InterCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ProQR Therapeutics and InterCure tied by winning 8 of the 16 factors compared between the two stocks.

How does InterCure compare to Pyxis Oncology?

InterCure (NASDAQ:INCR) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

InterCure has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.60	-$10.37M	$0.03	28.60
Pyxis Oncology	$13.86M	9.21	-$79.62M	-$1.31	N/A

Pyxis Oncology has a consensus target price of $6.83, suggesting a potential upside of 239.29%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

8.3% of InterCure shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 0.2% of InterCure shares are owned by insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Pyxis Oncology had 18 more articles in the media than InterCure. MarketBeat recorded 18 mentions for Pyxis Oncology and 0 mentions for InterCure. Pyxis Oncology's average media sentiment score of 0.20 beat InterCure's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Pyxis Oncology	Neutral

InterCure has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

InterCure's return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Pyxis Oncology	N/A	-135.60%	-85.00%

Summary

Pyxis Oncology beats InterCure on 9 of the 15 factors compared between the two stocks.

Get InterCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCR vs. The Competition

Export

Metric	InterCure	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$46.92M	$8.28B	$6.33B	$12.33B
Dividend Yield	N/A	2.52%	2.80%	5.36%
P/E Ratio	28.60	16.23	20.88	25.51
Price / Sales	0.60	8.61	520.50	73.06
Price / Cash	N/A	16.94	43.18	55.00
Price / Book	0.41	4.01	10.01	7.03
Net Income	-$10.37M	$224.05M	$3.54B	$334.92M
7 Day Performance	5.67%	2.51%	0.38%	-0.40%
1 Month Performance	12.88%	5.45%	-0.02%	1.07%
1 Year Performance	-44.82%	2.00%	35.07%	34.65%

InterCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCR InterCure	0.4851 of 5 stars	$0.85 -0.9%	N/A	-46.6%	$46.31M	$78.47M	28.23	350	Gap Up
IFRX InflaRx	2.7146 of 5 stars	$2.52 +3.7%	$7.00 +177.8%	+37.9%	$175.67M	$30K	N/A	60
ADAG Adagene	2.6238 of 5 stars	$3.70 +1.1%	$8.00 +116.2%	+121.2%	$173.43M	$7.67M	N/A	260	Gap Down
LFCR Lifecore Biomedical	1.558 of 5 stars	$4.50 -1.3%	$6.00 +33.3%	-31.1%	$171.04M	$128.87M	N/A	690
PRQR ProQR Therapeutics	3.3876 of 5 stars	$1.70 +6.3%	$7.25 +326.5%	-18.8%	$168.58M	$17.99M	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCR) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InterCure (INCR) Competitors

INCR vs. IFRX, ADAG, LFCR, PRQR, and PYXS

How does InterCure compare to InflaRx?

Summary

How does InterCure compare to Adagene?

Summary

How does InterCure compare to Lifecore Biomedical?

Summary

How does InterCure compare to ProQR Therapeutics?

Summary

How does InterCure compare to Pyxis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InterCure (INCR) Competitors

INCR vs. IFRX, ADAG, LFCR, PRQR, and PYXS

How does InterCure compare to InflaRx?

Do institutionals & insiders have more ownership in IFRX or INCR?

Do analysts recommend IFRX or INCR?

Does the media favor IFRX or INCR?

Which has preferable valuation & earnings, IFRX or INCR?

Which has more risk and volatility, IFRX or INCR?

Is IFRX or INCR more profitable?

Summary

How does InterCure compare to Adagene?

Do analysts rate ADAG or INCR?

Does the media refer more to ADAG or INCR?

Is ADAG or INCR more profitable?

Which has higher valuation and earnings, ADAG or INCR?

Which has more risk and volatility, ADAG or INCR?

Do institutionals and insiders believe in ADAG or INCR?

Summary

How does InterCure compare to Lifecore Biomedical?

Do analysts prefer LFCR or INCR?

Which has more risk and volatility, LFCR or INCR?

Do insiders & institutionals have more ownership in LFCR or INCR?

Does the media refer more to LFCR or INCR?

Is LFCR or INCR more profitable?

Which has preferable earnings & valuation, LFCR or INCR?

Summary

How does InterCure compare to ProQR Therapeutics?

Which has stronger valuation & earnings, PRQR or INCR?

Does the media refer more to PRQR or INCR?

Do analysts prefer PRQR or INCR?

Is PRQR or INCR more profitable?

Which has more risk & volatility, PRQR or INCR?

Do insiders and institutionals have more ownership in PRQR or INCR?

Summary

How does InterCure compare to Pyxis Oncology?

Which has higher valuation & earnings, INCR or PYXS?

Do analysts rate INCR or PYXS?

Do institutionals & insiders hold more shares of INCR or PYXS?

Does the media prefer INCR or PYXS?

Which has more volatility and risk, INCR or PYXS?

Is INCR or PYXS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools